← Back to Search

Cannabinoid

Smoked Cannabis Effects Study (S-TACOFS Trial)

Phase 1
Recruiting
Led By Ziva Cooper, PhD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or non-pregnant and non-lactating females aged 21-55 years
Male or non-pregnant and non-lactating females aged 21-55 years
Must not have
History of respiratory illness or current respiratory illness
Timeline
Screening 2 days
Treatment 1 month
Follow Up 0 days

Summary

This trial will study how different doses of inhaled cannabis with varying amounts of THC and CBD affects the body, as well as how long THC can be detected in oral fluid.

Who is the study for?
This trial is for men and women aged 21-55 who are not pregnant or breastfeeding, with a BMI of 18.5-34kg/m2, use cannabis weekly to monthly without seeking treatment, and agree to use contraception. Excluded are those with significant illness, other substance abuse disorders besides nicotine/caffeine, current heavy medication users, or those with respiratory issues.
What is being tested?
The study tests the effects of inhaled cannabis by comparing placebo (no THC/CBD), just THC (20 mg), just CBD (20 mg), and a combination of THC and CBD (20 mg each). It aims to understand how these substances affect the body and how they can be detected in oral fluid after smoking.
What are the potential side effects?
Potential side effects may include altered mental state due to THC intoxication, dizziness, dry mouth, changes in appetite or mood swings from both THC and CBD. Side effects vary based on individual tolerance levels.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man or a woman not pregnant or breastfeeding, aged 21-55.
Select...
I am a man or a woman not pregnant or breastfeeding, aged 21-55.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have or had a lung or breathing problem.

Timeline

Screening ~ 2 days
Treatment ~ 1 month
Follow Up ~0 days
This trial's timeline: 2 days for screening, 1 month for treatment, and 0 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Behavioral task performance as assessed by the DRUID App Score
Pharmacokinetics of THC, CBD and metabolites
Subjective drug effect ratings of impairment and abuse liability
+1 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: 20 mg THCExperimental Treatment1 Intervention
Smoked cannabis with THC
Group II: 20 mg CBD + 20 mg THCExperimental Treatment1 Intervention
Smoked cannabis with CBD and THC
Group III: 20 mg CBDExperimental Treatment1 Intervention
Smoked cannabis with CBD
Group IV: PlaceboPlacebo Group1 Intervention
Smoked placebo cannabis

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,569 Previous Clinical Trials
10,314,267 Total Patients Enrolled
12 Trials studying Substance Abuse
5,590 Patients Enrolled for Substance Abuse
Ziva Cooper, PhDPrincipal InvestigatorUniversity of California, Los Angeles
4 Previous Clinical Trials
375 Total Patients Enrolled

Media Library

CBD Cannabis (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT05037487 — Phase 1
Substance Abuse Research Study Groups: Placebo, 20 mg THC, 20 mg CBD + 20 mg THC, 20 mg CBD
Substance Abuse Clinical Trial 2023: CBD Cannabis Highlights & Side Effects. Trial Name: NCT05037487 — Phase 1
CBD Cannabis (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05037487 — Phase 1
Substance Abuse Patient Testimony for trial: Trial Name: NCT05037487 — Phase 1
~1 spots leftby Mar 2025